Abstract
The platelet receptor glycoprotein (GP)Ib-IX-V complex plays a dominant role in the first steps of platelet adhesion and arterial thrombus formation. Through its interaction with the multimeric plasma protein von Willebrand factor (VWF), which is bound to the damaged subendothelial structures, GPIb-IX-V tethers the platelets from the flowing blood thereby slowing them down. This step is a prerequisite for the collagen receptors to participate in firm adhesion resulting in the formation of a first platelet layer which is the basis for further thrombus formation. Recently, other ligands for GPIb-IX-V besides the extensively studied VWF have been identified, such as : α-thrombin, coagulation factor XII (FXII), high molecular weight kininogen (HMWK), factor XI (FXI), integrin Mac-1 and P-selectin. In this review, the interaction of GPIb-IX-V with its different ligands is described and the anticipated or demonstrated in vivo effects are discussed.
Keywords: Glycoprotein Ib, platelets, antithrombotic agents
Current Pharmaceutical Design
Title: Inhibition of Platelet Glycoprotein Ib and Its Antithrombotic Potential
Volume: 13 Issue: 26
Author(s): Karen Vanhoorelbeke, Hans Ulrichts, Gerlinde Van de Walle, Alexandre Fontayne and Hans Deckmyn
Affiliation:
Keywords: Glycoprotein Ib, platelets, antithrombotic agents
Abstract: The platelet receptor glycoprotein (GP)Ib-IX-V complex plays a dominant role in the first steps of platelet adhesion and arterial thrombus formation. Through its interaction with the multimeric plasma protein von Willebrand factor (VWF), which is bound to the damaged subendothelial structures, GPIb-IX-V tethers the platelets from the flowing blood thereby slowing them down. This step is a prerequisite for the collagen receptors to participate in firm adhesion resulting in the formation of a first platelet layer which is the basis for further thrombus formation. Recently, other ligands for GPIb-IX-V besides the extensively studied VWF have been identified, such as : α-thrombin, coagulation factor XII (FXII), high molecular weight kininogen (HMWK), factor XI (FXI), integrin Mac-1 and P-selectin. In this review, the interaction of GPIb-IX-V with its different ligands is described and the anticipated or demonstrated in vivo effects are discussed.
Export Options
About this article
Cite this article as:
Vanhoorelbeke Karen, Ulrichts Hans, de Walle Van Gerlinde, Fontayne Alexandre and Deckmyn Hans, Inhibition of Platelet Glycoprotein Ib and Its Antithrombotic Potential, Current Pharmaceutical Design 2007; 13 (26) . https://dx.doi.org/10.2174/138161207781662867
DOI https://dx.doi.org/10.2174/138161207781662867 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Food-derived bioactive peptides against chronic diseases
Chronic diseases, such as cardiovascular diseases and metabolic diseases, have become a great threat to the human health in recent decades due to the excessive food consumption and the prevalence of sedentary lifestyle. As a class of natural compounds, food-derived bioactive peptides have been demonstrated to possess great potential for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in the Treatment of Kidney Disorders using Mesenchymal Stem Cells
Current Pharmaceutical Design Metabolic Stress and Inflammation: Implication in Treatment for Neurological Disorders
CNS & Neurological Disorders - Drug Targets Immunosuppressive Properties of Mesenchymal Stem Cells: Advances and Applications
Current Molecular Medicine Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume II)
CNS & Neurological Disorders - Drug Targets MicroRNA-21: From Cancer to Cardiovascular Disease
Current Drug Targets Preface [Hot topic: Autoimmunity (Executive Editors: D. Stahl and W. Sibrowski)]
Current Pharmaceutical Design Inflammatory Caspases: Targets for Novel Therapies
Current Pharmaceutical Design Cardiovascular Drug Development Using Radiopharmaceuticals
Current Pharmaceutical Design Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Current Molecular Pharmacology Prognosis and Treatment of Ventricular Arrhythmias Following Myocardial Infarction
Current Cardiology Reviews Drug-Eluting Stents: Present and Future
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiac Oxidative Stress and Inflammatory Cytokines Response after Myocardial Infarction
Current Vascular Pharmacology The Role of Thrombomodulin in Atherosclerosis: From Bench to Bedside
Cardiovascular & Hematological Agents in Medicinal Chemistry Targeting Matrix Metalloproteinases in Inflammatory Conditions
Current Drug Targets Inhibition of sPLA2-IIA, C-reactive Protein or Complement: New Therapy for Patients with Acute Myocardial Infarction?
Cardiovascular & Hematological Disorders-Drug Targets The Innate Immune System and Fever under Redox Control: A Narrative Review
Current Medicinal Chemistry A Mechanistic Rationale for PDE-4 Inhibitors to Treat Residual Cognitive Deficits in Acquired Brain Injury
Current Neuropharmacology The Use of Genomics and Proteomics for the Recognition of Transplantation Rejection of Solid Organs
Recent Patents on DNA & Gene Sequences Stem Cells in Cardiovascular Regeneration: From Preservation of Endogenous Repair to Future Cardiovascular Therapies
Current Pharmaceutical Design Are the Antioxidant Properties of Carvedilol Important for the Protection of Cardiac Mitochondria?
Current Vascular Pharmacology